IV. Contenido técnico

A. Población objetivo de la PCV13:

1. Niños y niñas nacidos desde el primero de mayo del 2020, que inicien vacunación contra el neumococo.

2. Se continuará la vacunación con PCV13 a los siguientes grupos de riesgo:

   a) Prematuros menores de 36 semanas (peso de 2000 gramos).

   b) Enfermedad drepanocítica y otras hemoglobinopatías, asplenia congénita o adquirida y disfunción esplénica.

   c) Pacientes con VIH/SIDA.

   d) Condiciones de inmunosupresión incluyendo: deficiencias de linfocitos B (humoral) o linfocitos T; deficiencias de complemento, particularmente las fracciones C1, C2, C3 y C4 y trastornos fagocíticos, se excluye la enfermedad granulomatosa crónica.

   e) Insuficiencia renal y síndrome nefrótico.

   f) Enfermedades que requieren terapia inmunosupresora o radioterapia, incluyendo neoplasias malignas, leucemias, linfomas y enfermedad de Hodking y trasplantes de órganos sólidos.

   g) Enfermedades crónicas: cardiopatías, enfermedad pulmonar crónica, incluyendo asma tratada con dosis altas de esteroides, fugas de líquido cefalorraquídeo por malformaciones congénitas.

   h) Diabetes.

Estos pacientes deben presentar una indicación médica para recibir la vacunación.

Vacunación de puesta al día para los serotipos adicionales presentes en la PCV13.

Las niñas y niños nacidos desde el primero de marzo del año 2018 y que hayan recibido un esquema completo con PCV10 (2 dosis más un refuerzo), recibirán una dosis de PCV13, con un intervalo mínimo de 2 meses (8 semanas), luego de la última dosis de PCV10.

B. Población objetivo de la PCV10:

Niñas y niños sanos que hayan iniciado el esquema de vacunación contra el neumococo con PCV10, continuarán y terminarán esquema con PCV10.

C. Meta

Vacunar al 95 % de la población objetivo.

D. Estrategias de vacunación a utilizar

a) Vacunación intramural.

b) Se debe realizar vacunación en el cien por ciento de establecimientos de salud del MINSAL y del ISSS (unidades de salud, casas de salud, hospitales, unidades médicas, clínicas comunales del ISSS) a todas las niñas y niños del rango de edad descrito, que asisten a los servicios de salud, sean preventivos, curativos o como acompañantes de un familiar.

c) Vacunación *casa a casa*.

Se deben conformar equipos de vacunación que previa programación realizarán visitas casa a casa, estableciendo horarios de acuerdo a la conveniencia de la población de cada área geográfica de influencia.

d) Vacunación de poblaciones cautivas.

e) Vacunación en guarderías, asilos, entre otros.

E. Vacunas a utilizar

1. Vacuna PCV10:

Presentación: Suspensión inyectable, frasco unidosis.

Composición: cada dosis (0.5 ml) contiene: 1 microgramo de polisacárido de los serotipos 11,2, 51,2, 6B1,2, 7F1,2, 9V1,2, 141,2 y 23F1,2, y 3 microgramos de los serotipos 41,2, 18C1,3 y 19F1,4. 1 Adsorbido en fosfato de aluminio 0.5 miligramos Al3+. 2 Conjugado a proteína D, proteína transportadora (derivada de Haemophilus influenzae No Tipificable) [13] microgramos. [3] Conjugado a toxoide tetánico, proteína transportadora [8] microgramos. [4] Conjugado a toxoide diftérico, proteína transportadora [5] microgramos. Lista de excipientes: Cloruro de sodio; fosfato de aluminio y agua.

Acción terapéutica: vacuna conjugada y adsorbida de polisacárido neumocóccico y proteína D de Haemophilus influenzae No Tipificable (HiNT).

Dosis a aplicar

- El esquema consiste en dos dosis de 0.5 ml a partir del segundo mes de vida y una dosis de refuerzo.

- El intervalo mínimo entre la primera y segunda dosis es de cuatro semanas.

- Al igual que el resto de vacunas del programa regular, ésta se anotará en el respectivo carmé de vacunación.

2. Vacuna PCV13

Presentación: Suspensión Inyectable, frasco unidosis

Composición: Cada dosis (0.5 ml) contiene: Los principios activos son polisacáridos conjugados con CRM197 compuestos por:

2,2 µg de polisacáridos de los serotipos 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F y 23F, 4,4 µg de polisacárido del serotipo 6B, 32 µg de proteína transportadora CRM197 adsorbidos en fosfato de aluminio (0,125 mg de aluminio).

Los demás componentes son cloruro sódico, ácido succínico, polisorbato 80 y agua para preparaciones inyectables.

Acción Terapéutica:

PVC 13 es una vacuna antineumocócica para proteger contra enfermedades tales como: meningitis (inflamación alrededor del cerebro), sepsis o bacteriemia (bacterias en el torrente sanguíneo), neumonía (infección en el pulmón) e infecciones de oído, neumonía

Contraindicaciones: Hipersensibilidad a los principios activos o a alguno de los excipientes incluidos en la sección Excipientes o a alguna de las proteínas transportadoras. Como con otras vacunas, se debe posponer la administración de en sujetos que padezcan enfermedades febriles agudas. Sin embargo, la presencia de una infección leve, como un resfriado, no debe provocar el retraso de la vacunación.

Tabla N.º 1 Esquema de vacunación:

Edad	Dosis
2 meses	1ª dosis
4 meses	2ª dosis
1 año	Refuerzo

Fuente: Esquema Nacional de Vacunación de El Salvador, 2020.

Tabla N.º 2 Dosis para niños con esquema irregular:

Edad a la primera dosis	Series primarias	Dosis de refuerzo
2-11 meses	2 dosis	1 dosis
12-23 meses	2 dosis	
2 años a adultos	1 dosis	

Fuente: Esquema Nacional de Vacunación de El Salvador, 2020.

Modo de Empleo:

Antes de la administración, deberá examinarse visualmente el contenido del vial, tanto antes como después de agitar, en busca de cualquier material particulado extraño o cualquier aspecto físico anormal. En caso de que se observe cualquiera de estas anormalidades, desechar la vacuna. La vacuna deberá agitarse bien antes de su uso.

Modo de administración

Para uso intramuscular exclusivamente.

Menor de 1 año:



1 año:



Fuente: Manual de entrenamiento de Vacuna Conjugada siete Valente contra el neumococo, El Salvador, 2009.

F. Proceso para realizar acto vacunal

Paso 1:	Lavado de manos.
Paso 2:	• Leer siempre la etiqueta del frasco y verifique que corresponde a la vacuna indicada. • Verificar que no se haya llegado a la fecha de caducidad del vial, presencia de grumos.
Paso 3:	• Extraer 0.5 ml de la vacuna con una jeringa descartable de un solo uso de1ml: 23G X 1. • No se debe de mezclar con otras vacunas en el mismo vial o jeringa.
Paso 4:	Limpiar el área donde se va aplicar la vacuna con agua estéril.
Paso 5:	Administrar la vacuna mediante una inyección intramuscular en la parte antero lateral del muslo derecho del lactante.
Paso 6:	Al administrar simultáneamente la PCV13 o PCV10 con otras vacunas, cada una se debe aplicar en un lugar diferente. En el caso de un niño de 2 meses de edad: primero administrar la vacuna contra rotavirus que es oral, luego inyectar la IPV en el muslo derecho a nivel proximal, luego la vacuna neumococo PCV13 o PCV10, se aplicará en el mismo muslo a nivel distal a una distancia mínima de 2.5 cm entre cada una. Posteriormente se aplicará la vacuna Pentavalente en la región antero lateral del muslo izquierdo.
	Niña y niño de 4 meses: primero administrar la vacuna contra rotavirus que es oral, luego inyectar la IPV en el muslo derecho a nivel proximal, luego la vacuna neumococo PCV13 o PCV10, se aplicará en el mismo muslo a nivel distal a una distancia mínima de 2.5 cm entre cada una. Posteriormente se aplicará la vacuna Pentavalente en la región antero lateral del muslo izquierdo.
	Niña y niño de 1 año: Administrar la vacuna SPR en el brazo derecho y la vacuna PCV13 o PCV10, en el brazo izquierdo.
Paso 7:	Descartar inmediatamente la jeringa usada, sin re-tapar en una caja de seguridad.

Fuente: Lineamientos para la prevención y Control de Enfermedades Inmunoprevenibles 2015, El Salvador.

Registro de vacunas aplicadas

1. Niñas y niños menores de 5 años: registrar las dosis administradas en el libro de vacunación, en el formulario A, expediente clínico, así como en la cartilla de salud del niño(a) y anotar con lápiz la fecha de las siguientes dosis de las vacunas.
2. Personas con enfermedades crónicas, personal de salud: registrar las dosis administradas en el formulario C
3. Niños con vacunación puesta al día con PCV13: registrar la dosis administrada en el formulario C1 en la columna de Neumococo 13 Valente: niños de 2 a 18 años que inicien vacunación

G. Cuidados de la cadena de frío y calidad de la vacuna

Se debe garantizar el almacenamiento, mantenimiento y transporte de la vacuna en condiciones adecuadas, a una temperatura entre +2° y +8 °C, preservándola de la luz, ya que de lo contrario puede provocarse la inactivación de los virus.

Debe sacar los paquetes fríos del congelador y esperar entre 10 a 15 minutos o hasta que presentan sudoración en la superficie, antes de colocarlos en el termo.

Guardar la vacuna a temperatura entre +2º y +8 ºC para garantizar la potencia inmunizante de la vacuna.

H. Contraindicaciones para aplicar la vacuna

Hipersensibilidad a los principios activos o a alguno de los excipientes incluidos en la sección Excipientes o a alguna de las proteínas transportadoras. Como con otras vacunas, se debe posponer la administración en sujetos que padezcan enfermedades febriles agudas. Sin embargo, la presencia de una infección leve, como un resfriado, no debe provocar el retraso de la vacunación.

I. Efectos secundarios esperados

Al igual que todas las vacunas, PVC 13, puede producir efectos adversos, aunque no todas las personas los sufran.

Los efectos adversos observados con PVC 13, en lactantes y niños (de 6 semanas a 5 años de edad) incluyen los siguientes:

Los efectos adversos más frecuentes (los que pueden presentarse en más de 1 de 10 dosis de la vacuna) son:

Disminución del apetito.

Fiebre; irritabilidad; dolor, sensibilidad o dolor a la palpación en el lugar de vacunación, enrojecimiento, hinchazón o endurecimiento en el lugar de vacunación; somnolencia; sueño intranquilo.

Enrojecimiento, endurecimiento o hinchazón de 2,5 cm - 7 cm en el lugar de vacunación (tras la dosis de refuerzo y en niños de más edad [entre 2 y 5 años de edad]).

Los efectos adversos frecuentes (los que pueden presentarse hasta en 1 de 10 dosis administradas de la vacuna) son:

a) Vómitos, diarrea.

b) Fiebre de más de 39ºC; sensibilidad o dolor a la palpación en el lugar de vacunación que interfiere con los movimientos de la extremidad, enrojecimiento, hinchazón o endurecimiento de 2,5 cm - 7 cm en el lugar de vacunación (tras la serie inicial de inyecciones).

c) Erupción (rash).

Los efectos adversos poco frecuentes (los que pueden presentarse hasta en 1 de 100 dosis de la vacuna) son:

a) Convulsiones (o ataques), incluidas las causadas por una temperatura alta.

b) Ronchas (urticaria o erupción parecida a la urticaria).

c) Enrojecimiento, hinchazón o endurecimiento de más de 7 cm en el lugar de vacunación; llanto.

Los efectos adversos raros (los que pueden presentarse hasta en 1 de 1.000 dosis de la vacuna) son:

a) Colapso o estado similar al shock (episodio hipotónico con hiporrespuesta).

b) Reacción alérgica (hipersensibilidad), incluidas hinchazón de la cara y/o los labios, dificultad para respirar.

Los efectos adversos observados con PVC 13 en niños y adolescentes (de 6 a 17 años de edad) son los siguientes:

Más frecuentes (los que pueden presentarse en más de 1 de 10 dosis de la vacuna) son:

a) Disminución del apetito.

b) Irritabilidad; dolor, sensibilidad o dolor a la palpación, enrojecimiento, hinchazón o endurecimiento en el lugar de vacunación; somnolencia;

sueño intranquilo; sensibilidad o dolor a la palpación en el lugar de vacunación que interfiere con los movimientos de la extremidad.

Frecuentes (los que pueden presentarse hasta en 1 de 10 dosis de la vacuna) son:

a) Cefaleas.

b) Vómitos, diarrea.

c) Erupción (rash); ronchas (urticaria o erupción similar a la urticaria).

d) Fiebre.

Los niños y adolescentes con infección por el VIH, anemia falciforme o que se habían sometido a un trasplante de las células madre presentaron efectos adversos similares; sin embargo, la frecuencia de cefalea, vómitos, diarrea, fiebre, fatiga, dolor de articulaciones y dolor muscular, fueron muy frecuentes.

J. Que hacer ante los eventos supuestamente asociados a la vacunación (ESAVI)

1. Todos los ESAVI serios y no serios (eventos o incidentes adversos post-vacunales, conocidos o desconocidos para la vacuna) y los errores programáticos (surgidos por la falta de observancia de las contraindicaciones o incumplimiento de la normativa) que sean detectados, debe notificarse al Centro Nacional de Farmacovigilancia utilizando el formulario de notificación de ESAVI, el cual puede obtenerse en la siguiente dirección electrónica: .http://cnfv.salud.sv/.

2. Frente a una emergencia durante el proceso de vacunación, debe velar por la seguridad y la asistencia rápida del afectado(a). Si alguna persona presenta un cuadro alérgico post-vacunal, con características de shock, provea atención inmediata. Consulte con un médico y refiera inmediatamente al establecimiento de salud más cercano. Acompañe al paciente y garantice que su traslado sea seguro y sea atendido de forma oportuna y adecuada. Recuerde que todo ESAVI serio detectadc (eventos o incidentes adversos post-vacunales que pongan en riesgo la vida, amerite atención especializada, hospitalización o con riesgo de incapacidad), debe recibir la atención médica inmediata para restituir la salud y preservar la vida, utilizando todos los recursos disponibles y ayudas diagnósticas debidas.

3. Todos los eventos o incidentes adversos post-vacunales serios (que pongan en riesgo la vida, hospitalizaciones, riesgos de incapacidad y muertes postvacunales), incluyendo los rumores relacionados con la vacunación, deben ser investigados inmediatamente (dentro de las 24 horas posteriores a su detección) y notificados de inmediato al Centro

Nacional de Biológicos (tel: 22314811), a la Región de Salud y SIBASI correspondientes, o sin son beneficiarios del ISSS al teléfono 70397016, 73084416 o al 70711279 en el formulario de notificación de ESAVI establecido.

4. Toda investigación de eventos o incidentes adversos post-vacunales serios (ESAVI serios) incluyendo los rumores relacionados con la vacunación, deben seguir y contener como mínimo la información establecida en la "Guía para el Seguimiento de Eventos Supuestamente Atribuibles a la Vacunación e Inmunización Serios y Abscesos | fv-02-cnfv.gui01 | versión 01", la cual puede obtenerse en la página web del Centro Nacional de Farmacovigilancia, en la siguiente dirección electrónica: http://cnfv.salud.sv/download/guia-para-el-seguimiento-de-eventos supuestamente-atribuibles-a-la-vacunacion-e-inmunizacion-serios-y-abscesos-fv-02-cnfv-gui01-version-01/ y se debe dar seguimiento hasta su recuperación o resolución de la situación.

K. Manejo de desechos sólidos hospitalarios peligrosos (DSHP)

Recomendaciones generales:

1. La clasificación de los DSHP Infecciosos es el primer paso hacia una gestión segura y efectiva. A partir de una absoluta claridad sobre lo que son los desechos peligrosos para la salud, se pueden poner en práctica procedimientos de manejo y de tratamiento seguros para los trabajadores, el medio ambiente y la comunidad.

2. Son DSHP Infecciosos los generados por los servicios de vacunación, la sangre de pacientes y materiales empapados o saturados de sangre aunque se hayan secado, así como los recipientes que los contienen o que se contaminaron, como bolsas plásticas, entre otros.

3. También son importantes los elementos punzo cortantes, que estuvieron en contacto con fluidos corporales o agentes infecciosos, incluyendo agujas hipodérmicas, jeringas, cristalería entera o rota, aún cuando no haya sido usado.

4. La administración de cada establecimiento de salud, es la responsable del abastecimiento adecuado de los insumos necesarios, con el objetivo de proteger la salud del personal, de los pacientes, de la población en general y el medio ambiente, así como de mejorar las condiciones de seguridad e higiene en el trabajo; de evitar contaminación de los desechos; de cumplir con las reglamentaciones vigentes o promover su regulación.

5. Los colores facilitan la labor de los operadores en la actividad de separación, para evitar errores en las fases de transporte, almacenamiento y tratamiento de los DSH/P Infecciones. El color negro se utiliza para los desechos comunes y el color Rojo, para los desechos peligrosos.

8. Una vez que los envases de DSH/P infecciosos, se encuentran llenos y han sido sellados, deben ser etiquetados, ya que esto permite identificar claramente la tipología y peligrosidad del contenido, aun en ausencia de símbolos en los envases, y evitar un manejo incorrecto y mezcla de desechos de diferentes tipos en la fase de almacenamiento temporal.

9. Una vez llenado el contenedor, se cierra cuidadosamente, se etiqueta y se coloca en un lugar de acumulación, este debe estar aislado y contar con suficiente ventilación. Además bajo ninguna circunstancia se deberán mantener a la intemperie.

10. Cuando se traten de materiales perforables (bolsas de plástico), el personal de limpieza debe tomarlos desde arriba y mantenerlos alejados del cuerpo, a fin de evitar roces y posibles accidentes con punzo cortantes mal segregados.

L. Manejo de objetos cortopunzantes:

Para el manejo de punzo cortantes son necesarias las siguientes precauciones:

1. Segregar todos los punzo cortantes y las agujas en las cajas de seguridad, proporcionadas por el Centro Nacional de Biológicos o en su defecto en recipientes plásticos resistentes.
2. Cada caja de seguridad tienen capacidad para 100 jeringas.
3. Estos recipientes no deberán llenarse más de dos tercios de su volumen.
4. El recipiente, una vez llenado, tiene que cerrarse firmemente, operación que se realizará en el mismo lugar de generación.
5. Los punzo cortantes, una vez depositados en sus envases, no deben ser removidos por ninguna razón.
6. Se deberán acoplar los contenedores en las bolsas rojas y etiquetarlos como punzo cortantes.
7. El ISSS hará el proceso de descarte de los punzo cortantes en las cajas de seguridad y utilizará el servicio de manejo de desechos sólidos bioinfecciosos establecidos en norma.
8. En caso de envío directo al relleno sanitario, sin ser sometidos a un sistema de tratamiento, es oportuno descontaminar previamente por vía química todos los punzo cortantes, llenando el recipiente con una solución desinfectante (por ejemplo, hipoclorito de sodio o de cal).

V. Disposiciones finales

Sanciones por el incumplimiento

Todo incumplimiento al presente instructivo, será sancionado de acuerdo a lo prescrito en las normativas administrativas pertinentes.

De lo no previsto

Lo que no esté previsto en el presente instructivo, se debe resolver a petición de parte, por medio de escrito dirigido al Titular de esta Cartera de Estado, fundamentando la razón de lo no previsto técnica y jurídicamente.

VI. Vigencia

El presente instructivo entrará en vigencia a partir de la fecha de su oficialización por parte del Titular.

San Salvador a días del mes de del año dos mil veinte.

Dr. Francisco José Alabí Montoya
Ministro de Salud *ad honórem*

GOBIERNO DE EL SALVADOR

MINISTERIO DE SALUD

DIREECCION NACIONAL DE ENFERMEDADES INFECCIOSAS
PROGRAMA DE VACUNACIONES E INMUNIZACIONES

COBERTURAS DE NEUMOCOCO DE ENERO-ABRIL 2020

Vacuna	DIGESTYC					NACIDOS VIVOS				
	Dosis Aplicada	Poblacion	Cobertura	Población Ajustada para el periodo	Cobertura	Dosis Aplicadas	Poblacion	Cobertura	Población Ajustada para el periodo	Cobertura
Neumo 2	22,716	109,274	21%	36,425	62%	22,716	86,353	26%	27,199	84%
Neumo 3	20,247	109,690	18%	36,656	55%	20,247	86,353	23%	28,784	70%

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

To:

WYETH HOLDINGS LLC
500 Arcola Road
Collegeville, PA 19426
United States of America
Attn: Ms. Erika Pagani

Ship To:

MINISTERIO DE SALUD, CENTRO NACIONAL DE BIOLOGICOS
Calle Antigua al Matazano atrás de la Cancha de la Constancia Bulevar del Ejercito
Attn: Dra. Nora Villatoro, Jefe Centro de Biológicos / Licda. Sonia Quintanilla, Administradora Centro de Biológicos
San Salvador
El Salvador
Email: nvillatoro@salud.gob.sv / Tel: +503 (2297) 5578

#	DESCRIPTION	QUANTITY	UNIT	UNIT PRICE	CURRENCY	TOTAL AMOUNT
1	**PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT PEDIATRIC 1 DS VIAL** LABELS: ENGLISH INSERTS: MULTILINGUALS INCLUDING SAPNISH SHELF LIFE: 18 MONTHS MINIMUM AT THE TIME OF SHIPMENT REGISTRATION: NOT REGISTERED	312,000	Dose	14.500000	USD	4,524,000.00
2	**DISCOUNT PCV-13 2020** NOTE: DISCOUNT ACCORDING TO PAHO SUPPLY AGREEMENT. NET PRICE: US$13.56/DOSE	1	Each	-293,280.00	USD	-293,280.00
3	**AIR FREIGHT CHARGES/CARGOS POR FLETE AEREO**				USD	43,800.00
4	**INSURANCE CHARGES/CARGOS POR SEGURO**				USD	2,494.00

ESTIMATED DELIVERY DATE: 23-Apr-2020

PAHO'S CONTACT: JAIME A. SAAVEDRA - SAAVEDRJ@PAHO.ORG - +1 (202) 974-3912

PAYMENT TERMS: NET 30

INCOTERMS 2020: DPU - INTERNATIONAL AIRPORT SAN SALVADOR, EL SALVADOR

TERMS:

****

GOODS SHOULD BE PROPERLY PACKED FOR INTERNATIONAL FREIGHT TRANSPORT.
SHIPMENT MUST BE INSURED AND FREIGHT PREPAID.

QUOTATION: AS PER SUPPLY AGREEMENT AND YOUR QUOTE: REQ20-00002462

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

ALL SHIPPING DOCUMENTS AND PACKAGES MUST INCLUDE THE FOLLOWING MARKS:

APO No.: APO20-00006260 (RV)
REQ No.: REQ20-00002462 (RV)

• DO NOT CONSOLIDATE OR MAKE PARTIAL SHIPMENTS WITHOUT WRITTEN PRIOR APPROVAL FROM PAHO.
• USE THE MOST DIRECT ROUTE POSSIBLE. IF A DIRECT ROUTE IS NOT AVAILABLE THE NUMBER OF TRANSFER POINTS SHOULD BE HELD TO THE MINIMUM AND MUST NOT EXCEED 72 HOURS OF TRANSIT TIME.
• THE SUPPLIER MUST INFORM PAHO/PRO OF ANY DELAYS IN DELIVERY AT LEAST TWO WEEKS PRIOR DEPARTURE OF SHIPMENT FROM POINT OF ORIGIN.
• IN THE TRANSPORTATION DOCUMENT, UNDER THE CAPTIONS, "RATE/CHARGE" AND/OR "TOTAL", INCLUDE THE APPROPRIATE FIGURES IN LOCAL CURRENCY OR IN UNITED STATES DOLLARS. AIRWAY BILL(S) OR BILL OF LADING(S) CONTAINING CLAUSES SUCH AS "AS AGREED", "AS ARRANGED" OR UNRATED ARE NOT ACCEPTABLE.
• THE COMMERCIAL INVOICE MUST BE SIGNED AND STAMPED, AND IT SHALL SHOW THE INCOTERM AS PER PURCHASE ORDER AND THE AMOUNTS OF GOODS, FREIGHT AND INSURANCE MUST BE ITEMIZED SEPARATELY.
• THE DESCRIPTION OF GOODS MUST BE IN SPANISH, WHEN SHIPPING TO SPANISH SPEAKING COUNTRIES.
• PRIOR TO SHIPMENT, EMAIL COMPLETE SHIPPING DETAILS AND DOCUMENTS TO PAHO'S CONTACT AS INDICATED ABOVE.
• DO NOT PROCEED WITH SHIPMENT IF ANY DOCUMENTATION LISTED ON THIS PURCHASE ORDER IS NOT READY OR VALID.
• REGARDLESS INCOTERM STATED ON PURCHASE ORDER, THE SUPPLIER SHALL PROVIDE INSURANCE OF SHIPMENT AGAINST ALL RISKS (EXCEPT FOR ORDERS PLACED UNDER EXW OR DDP INCOTERMS) IN THE MINIMUM AMOUNT OF 110% OF THE TOTAL VALUE OF THE PURCHASE ORDER.

EMAIL INVOICES FOR PAYMENT TO THE PAN AMERICAN HEALTH ORGANIZATION, WASHINGTON D.C.

****

ACCEPTANCE OF THIS ORDER IS EXPRESSLY LIMITED TO THE GENERAL TERMS AND CONDITIONS ATTACHED THERETO.

****

VACCINE INSTRUCTIONS

SHIPMENTS SHALL BE BOOKED AND DELIVERED IN ACCORDANCE WITH THE INSTRUCTIONS BELOW. ANY ADDITIONAL CHARGE INCURRED AT DESTINATION DUE TO NON-COMPLIANCE OR DELAY IN PROVIDING INFORMATION, SUCH AS FLIGHT INFORMATION, DOCUMENTS PROVIDED IN LESS THAN FIVE DAYS OF THE ETA, LACK OF AWB FOR THE LAST FLIGHT SEGMENT TO THE DESTINATION COUNTRY, DELIVERY WITHOUT NOTIFICATION, UNAUTHORIZED WEEKEND ARRIVALS, OR ANY DOCUMENT REQUESTED IN THIS PURCHASE ORDER, SHALL BE COVERED BY THE SUPPLIER.

LABELLING AND TEMPERATURE CONTROL

• THE SUPPLIER MUST INCLUDE ONE WHO PREQUALIFIED ELECTRONIC SHIPPING INDICATOR WITH USB INTERFACE PER INSULATED SHIPPING UNIT AND THE CONTENT OF THE DEVICE SHALL BE READABLE WITHOUT THE NEED OF SPECIAL SOFTWARE OF ANY KIND.
• FOR INSULATED SHIPPING UNITS EXCEEDING 800MM IN HEIGHT, IT IS RECOMMENDED THE USE OF TWO DEVICES POSITIONED ACCORDING TO THE COLD AND HOT SPOTS IDENTIFIED IN THE THERMAL-MAPPING.
• A LABEL OR MARKING SHOULD BE AFFIXED ON THE OUTER SHIPPING UNIT INDICATING THE MAXIMUM

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

STACKING CAPACITY OR "DO NOT STACK".
• TO AVOID DAMAGE OF GOODS AT DESTINATION, IT IS RECOMMENDED THAT THE SECONDARY PACKAGE CONTAINS MARKINGS INDICATING THE MAXIMUM NUMBER OF BOXES THAT CAN BE STACKED.
• A "DO NOT FREEZE" WATER RESISTANT LABEL MUST BE PLACED ON EACH FACE OF THE INSULATED SHIPPING UNITS CONTAINING FREEZE-SENSITIVE PRODUCTS.
• THE "VACCINE URGENT" LABEL MUST BE PLACED ON EACH FACE OF THE OUTER INSULATED SHIPPING UNITS FOR ALL SHIPMENT OF THE VACCINES, IN THE LANGUAGE OF THE DESTINATION COUNTRY.
• A PROPER TEMPERATURE RANGE IATA TIME AND TEMPERATURE SENSITIVE LABEL MUST BE PLACED ON EACH FACE OF THE INSULATED SHIPPING UNIT.
• THE STORAGE TEMPERATURE MUST BE CLEARLY INDICATED ON THE INSULATED SHIPPING UNIT WITH THE MANUFACTURER'S RECOMMENDED TEMPERATURE RANGE, WHICH SHOULD BE VISIBLE FOR PERSONNEL HANDLING THE GOODS DURING TRANSIT OR AT DESTINATION.

SHIPPING INSTRUCTIONS
AS PER OUR BID SOLICITATION FOR THIS PRODUCT

I- BOOKING

BIOLOGICAL PRODUCTS SHIPMENTS ARE TO BE BOOKED AS TEMPERATURE CONTROL CARGO. BOOKINGS SHOULD BE REQUESTED WELL IN ADVANCE AND FLIGHT DETAILS SHALL BE FURNISHED TO PAHO BY E-MAIL ONLY IN NO LESS THAN FIVE BUSINESS DAYS PRIOR TO THE DATE OF ARRIVAL OF THE PRODUCT. UNLESS OTHERWISE SPECIFIED BY PAHO, THE NOTIFICATION OF FLIGHT DETAILS SHALL INCLUDE:

• PURCHASE ORDER (APO NO.) AND REQUISITION (REQ NO.) NUMBERS
• DATE AND TIME OF DEPARTURE AND ARRIVAL, AIRLINE FLIGHT NUMBER(S), ALL TRANSIT ROUTES AND DATES AND PORT OF ENTRY
• AIRWAY BILL NUMBER(S)
• NUMBER OF PIECES, GROSS WEIGHT AND PACKAGING SPECIFICATION [PALLETS, ENVIROTAINERS, DRY ICE ETC. (IF APPLICABLE)].
• TYPE OF TEMPERATURE SHIPPING INDICATORS INCLUDED IN THE SHIPMENT AND TEMPERATURE RANGE THAT PRODUCT SHOULD BE STORED

II- DELIVERY

• HOUSE AIRWAY BILLS OR BACK-TO-BACK CONSIGNMENTS ARE NOT PERMITTED FOR THE FINAL FLIGHT SEGMENT UNLESS APPROVED IN WRITING IN ADVANCE BY PAHO.
• ALL SHIPPING DOCUMENTS MUST SHOW COMPLETE CONSIGNEE ADDRESS, AS IT IS SHOWN IN THE SHIP TO FIELD OF THE PURCHASE ORDER.
• DO NOT SHIP BIOLOGICAL PRODUCTS TO ARRIVE AT DESTINATION ON FRIDAYS, WEEKEND OR HOLIDAYS, EXCEPT IF AUTHORIZED BY PAHO.
• ALL VACCINES AND IMMUNOGLOBULIN SHIPMENTS MUST BE ACCOMPANIED BY ORIGINALS OF SHIPPING DOCUMENTS.
• DO NOT SHIP BIOLOGICAL PRODUCTS VIA COURIER, EXCEPT WITH A WRITTEN AUTHORIZATION FROM PAHO.

III- INFORMATION TO BE INCLUDED IN THE AIRWAY BILL:

• THE FOLLOWING NOTATION SHALL BE INCLUDED IN THE BODY OF THE AWB: "CONSIGNEE SHALL ARRANGE FOR IMMEDIATE COLLECTION" AND "FREIGHT AGENT/CARRIER SHALL INFORM CONSIGNEE AND PAHO W.D.C.

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

IMMEDIATELY BY PHONE AND/OR EMAIL IF THE SHIPMENT DOES NOT ARRIVE."
• UNDER THE CAPTION, "CONSIGNEE'S NAME AND ADDRESS": COMPLETE CONSIGNEE'S INFORMATION AS STATED IN THE PURCHASE ORDER.
• UNDER THE CAPTION, "HANDLING INFORMATION", THE NOTATION: "BIOLOGICAL PRODUCT FOR HUMAN USE, HIGHLY PERISHABLE, DO NOT DELAY." THIS FIELD MUST ALSO INDICATE THE MANUFACTURER'S RECOMMENDED TEMPERATURE RANGE IN CELSIUS.
• ALL AIRWAY BILL(S) MUST BE RATED.
• THE DESCRIPTION OF THE GOODS IN THE AIRWAY BILL, MUST MATCH THE GENERIC DESCRIPTION OF THE GOODS IN THE COMMERCIAL INVOICE.

IV- REQUIRED DOCUMENTS FOR VACCINES AND IMMUNOGLOBULIN SHIPMENTS

• COMMERCIAL INVOICE AND PACKING LIST. THE PACKING LIST AND OR INVOICE MUST SHOW GROSS AND NET WEIGHTS, BATCH NUMBERS, QUANTITY AND EXPIRATION DATE(S)
• AIRWAY BILL, INSURANCE CERTIFICATE
• A PACKING SLIP IDENTIFYING THE ELECTRONIC SHIPPING INDICATOR NUMBER (S) WITH THE INSULATED SHIPPING UNIT NUMBER(S)
• CERTIFICATE OF ORIGIN ISSUED BY THE CHAMBER OF COMMERCE
• CERTIFICATE OF GOODS MANUFACTURING PRACTICES (GMP)
• CERTIFICATE OF PHARMACEUTICAL PRODUCT (CPP) OR THE FREE SALE CERTIFICATE (FSC) ISSUED FOR THE RECIPIENT COUNTRY OR INCLUDE AN ANNEX WITH THE LIST OF IMPORTING COUNTRIES (MULTI-COUNTRY).
• CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT (AND DILUENT, WHEN APPLICABLE. DILUENTS EXPIRATION DATE MUST BE EQUAL OR LONGER THAN THAT OF THE VACCINE)
• LOT RELEASE CERTIFICATE ISSUED BY THE COUNTRY OF ORIGIN NATIONAL REGULATORY AUTHORITY (NRA) FOR FINISH PRODUCT (IF FINAL LOT NUMBER IS NOT MENTIONED IN THE CERTIFICATE OF RELEASE, THE VENDOR SHOULD ISSUE A STATEMENT WITH THE PROPER EXPLANATION).
• SUMMARY PROTOCOL OF MANUFACTURING AND QUALITY CONTROL. BIOLOGICAL PRODUCTS SHALL CONFORM TO THE GENERAL AND PRODUCT SPECIFIC GUIDELINES RELATED TO PRODUCTION, QUALITY, SAFETY, EFFICACY AND POTENCY ADOPTED BY WHO EXPERT COMMITTEES. HTTP://WWW.WHO.INT/BIOLOGICALS/EN/
• CERTIFICATE OF PLASMA POOLS (IF HUMAN PLASMA DERIVATIVE PRODUCTS)

V- DOCUMENTS DISTRIBUTION

UNLESS OTHERWISE INDICATED BY PAHO IN THE PURCHASE ORDER, ONE ORIGINAL SET OF THE REQUIRED DOCUMENTS (ABOVE MENTIONED) SHALL BE SENT TO THE CONSIGNEE (BY COURIER) AS FAR IN ADVANCE OF SHIPMENT AS POSSIBLE, TO FACILITATE INITIATION OF THE CUSTOMS CLEARANCE PROCESS PRIOR TO THE ARRIVAL OF THE PRODUCT. THE COURIER TRACKING INFORMATION SHALL BE PROVIDED TO THE PAHO WASHINGTON D.C. ANOTHER ORIGINAL SET SHALL ACCOMPANY THE SHIPMENT. FINALLY, PRIOR TO THE DEPARTURE OF THE SHIPMENT, A FULL SET OF SUCH DOCUMENTS SHALL BE EMAILED TO PAHO IN WASHINGTON D.C. PLEASE REFER TO THE DOCUMENTS DISTRIBUTION BELOW FOR FURTHER GUIDANCE.

****DOCUMENTS TO BE SHIPPED WITH THE SHIPMENT****

· AIR WAYBILL (ALL ORIGINALS)
· COMMERCIAL INVOICE (ORIGINAL)
· PACKING LIST (ORIGINAL)

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037

Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

· INSURANCE CERTIFICATE (COPY)
· CERTIFICATE OF ORIGIN ISSUED BY THE CHAMBER OF COMMERCE (ORIGINAL)
· LOT RELEASE CERTIFICATE FROM THE NATIONAL REGULATORY AUTHORITY NRA (COPY)
· CERTIFICATE OF ANALYSIS FOR FINISHED PRODUCT (AND DILUENT, WHEN APPLICABLE) (COPY)
· FREE SALE CERTIFICATE OR CPP (COPY)
· SUMMARY PROTOCOL OF MANUFACTURING AND QUALITY CONTROL (COPY)
· CERTIFICATE OF PLASMA POOLS (IF HUMAN PLASMA DERIVATIVE PRODUCTS (ORIGINAL – IF APPLICABLE)

****DOCUMENTS TO BE SEND VIA COURIER TO CONSIGNEE AT LEAST 5 DAYS PRIOR TO THE ARRIVAL OF THE SHIPMENT****

· AIR WAYBILL (COPY)
· COMMERCIAL INVOICE (ORIGINAL)
· PACKING LIST (ORIGINAL)
· INSURANCE CERTIFICATE (ORIGINAL)
· CERTIFICATE OF ORIGIN ISSUED BY THE CHAMBER OF COMMERCE (COPY)
· LOT RELEASE CERTIFICATE FROM THE NATIONAL REGULATORY AUTHORITY NRA (COPY)
· FREE SALE CERTIFICATE OR CPP (COPY)

VENDORS MUST PROVIDE COURIER TRACKING INFORMATION TO PAHO'S PROCUREMENT OFFICE BY EMAIL. ANY COSTS RELATED TO THIS SERVICE SHALL BE ITEMIZED AND INVOICED TOGETHER WITH THE FREIGHT AND INSURANCE CHARGES.

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037

Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

IN ORDER TO PROCEED WITH THIS PURCHASE ORDER, A SIGNED COPY OF THIS PAGE MUST BE RETURNED (ATTENTION PROCUREMENT AND SUPPLY MANAGEMENT AREA -PRO), VIA EMAIL OR MAIL, THEREBY INDICATING THAT THE TERMS AND CONDITIONS OF THIS PURCHASE ORDER ARE ACCEPTED.
TO RECEIVE PAYMENT VIA WIRE TRANSFER DIRECTLY INTO YOUR BANK ACCOUNT, INDICATE THE FOLLOWING INFORMATION ON EACH INVOICE:

BENEFICIARY NAME
BANK NAME
BANK ADDRESS
BANK ROUTING CODE, SWIFT CODE, OR ABA
ACCOUNT NUMBER
YPE OF ACCOUNT
INTERMEDIARY BANK
INTERMEDIARY BANK ADDRESS
INTERMEDIARY BANK ROUTING

ALL INVOICES RELATED TO THIS PURCHASE ORDER MUST BE SUBMITTED FOR PAYMENT NO LATER THAN NINETY(90) DAYS AFTER FINAL SHIPMENT IS EFFECTED.

NAME/TITLE	SIGNATURE	DATE

To:

WYETH HOLDINGS LLC
500 Arcola Road
Collegeville, PA 19426
United States of America

Attn: Ms. Ericka Pagani

Document Total: **USD 4,277,014.00**

3 Apr 2020

Daniel Rodriguez **Date**
Procurement Director

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

GENERAL TERMS AND CONDITIONS: CONTRACTS FOR GOODS AND/OR SERVICES

1. **LEGAL STATUS OF THE PARTIES/RESPONSIBILITY FOR EMPLOYEES:** The Contractor shall be considered as having the legal status of an independent contractor to PAHO. The Contractors personnel and sub-contractors shall not be considered in any respect to be the employees or agents of PAHO and shall have no right or authority, express or implied, to commit or otherwise obligate PAHO to a third party in any way. The Contractor shall be responsible for the professional and technical competence of the personnel it assigns to perform services under the Contract and will select reliable and competent individuals who will be able to effectively perform the obligations under the Contract and who, while doing so, will respect the local laws and customs and conform to a high standard of moral and ethical conduct.

2. **STANDARD OF PERFORMANCE:** The Contractor agrees that the goods and/or services provided under this Contract shall conform to the highest professional standards. The Contractor shall conform to all applicable laws, regulations and ordinances promulgated by the government of the country in which the goods or services are provided. Further, the Contractor agrees to utilize any information and/ or documents obtained from or provided by PAHO for the purpose of the Contract exclusively for the activities agreed upon between PAHO and the Contractor.

3. **ASSIGNMENT:** The Contractor shall not assign, transfer, pledge or make other disposition of this Contract, or any part thereof, or of any of the Contractors rights or obligations hereunder, without the prior written authorization of PAHO. In addition, the assignee or transferee must agree in writing to be bound by all terms and conditions of this Contract.

4. **SUBCONTRACTING:** The Contractor shall first obtain the written approval of PAHO before subcontracting to a third party any of the Contractors responsibilities under this Contract. PAHOs approval shall not relieve the Contractor of any of its obligations under this Contract. The terms of any sub-contract shall be subject to and conform to the provisions of this Contract.

5. **PURCHASE OF GOODS:** If the Contract involves, in whole or in part, the purchase of goods, the following conditions shall apply unless specifically stated otherwise in the Contract.

   5.1 **PACKAGING OF THE GOODS:** The Contractor shall package the goods for delivery in accordance with the highest standards of packaging for the type and quantities and modes of transport of the goods. The goods shall be packed and marked in a proper manner in accordance with the shipping instructions attached to the Contract or, otherwise, as customarily done in the trade, and in accordance with any requirements imposed by applicable law, including regulations for the transportation of hazardous materials, or by the transporters and manufacturers of the goods as per International Standards

   5.2 **EXPORT LICENSING:** The Contractor shall be responsible for obtaining any export licenses required with respect to the goods, products, or technologies, including software that is sold, delivered, licensed or otherwise provided to PAHO or its designee under the Contract. The Contractor shall procure any such license in an expeditious manner.

   5.3 **TRANSPORTATION AND FREIGHT:** Unless otherwise specified in the Contract, the Contractor shall be solely liable for making all transport arrangements and for payment of freight and insurance costs for the shipment and delivery of the goods in accordance with the requirements of the Contract. The Contractor shall ensure that PAHO or its designee receives all necessary transport documents in a timely manner so as to enable PAHO or its designee to take delivery of the goods in accordance with the requirements of the Contract.

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

5.4 DELIVERY OF GOODS: The Contractor shall hand over or make available the goods, and PAHO or its designee shall receive the goods, at the place and time designated under the Contract for their delivery. The Contractor shall provide to PAHO or its designee such shipment documentation (including, without limitation, bills of lading, airway bills, and commercial invoices) as are specified in the Contract or, otherwise, as are customarily utilized in the trade. All manuals, instructions, displays and any other information relevant to the goods shall be in the English language unless otherwise specified herein. The entire risk of loss, damage to, or destruction of the goods shall be borne exclusively by the Contractor until physical delivery of the goods to PAHO or its designee in accordance with the terms of the Contract. Delivery of the goods shall not be deemed in itself as constituting acceptance of the goods by PAHO.

5.5 INSPECTION OF GOODS: If the Contract provides that the goods may be inspected prior to delivery, the Contractor shall notify PAHO or its designee when the goods are ready for pre-delivery inspection. Notwithstanding any pre-delivery inspection, PAHO or its designated inspection agents may also inspect the goods upon delivery in order to confirm that the goods conform to applicable specifications or other requirements of the Contract.

5.6 ACCEPTANCE OF GOODS: Under no circumstances shall PAHO or its designee be required to accept any goods that do not conform to the specifications or requirements of the Contract. PAHO or its designee may condition its acceptance of the goods upon the successful completion of acceptance tests as may be specified in the Contract or otherwise agreed in writing by the Parties. In no case shall PAHO or its designee be obligated to accept any goods unless and until PAHO or its designee has had a reasonable opportunity to inspect the goods following delivery. If the Contract specifies that PAHO or its designee shall provide a written acceptance of the goods, the goods shall not be deemed accepted unless and until PAHO or its designee in fact provides such written acceptance. In no case shall payment by PAHO, in and of itself, constitute acceptance of the goods.

5.7 REJECTION OF GOODS: Notwithstanding any other rights or remedies available to PAHO under the Contract, if any of the goods are defective or otherwise do not conform to the specifications or other requirements of the Contract, PAHO or its designee, at their sole option, may reject or refuse to accept the goods. Within thirty (30) days following receipt of notice from PAHO of such rejection or refusal to accept the goods, the Contractor shall, at PAHOs sole discretion and at no additional expense to PAHO, either:

5.7.1 provide a full refund upon return of the goods, or a partial refund upon a return of a portion of the goods, by PAHO or its designee;

5.7.2 repair the goods in a manner that would enable the goods to conform to the specifications or other requirements of the Contract; or

5.7.3 replace the goods with goods that meet the specifications of the Contract.

5.8 In the event that PAHO or its designee elects to return any of the goods for the reasons specified in this Article, PAHO may procure the goods from another source. In addition to any other rights or remedies available to PAHO under the Contract, including, but not limited to, the right to terminate the Contract, the Contractor shall be liable for any additional cost beyond the balance of the Contract price resulting from any such procurement, including, inter alia, the costs of engaging in such procurement. Likewise, the Contractor shall pay all costs relating to the repair or return of the defective goods as well as the costs relating to the storage of any such defective goods and for the delivery of any replacement goods to PAHO or its designee.

6. WARRANTIES: In addition to and without limiting any other warranties, remedies or rights of PAHO stated in or arising under the

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

Contract, the Contractor warrants and represents that:

6.1 The goods, including all packaging and packing thereof, and/or Services to be provided under the Contract conform to the specifications of the Contract, are fit for the purposes for which they are ordinarily used and for any purposes expressly made known in writing in the Contract, and shall be of even quality, free from faults and defects in design, material, manufacturer and workmanship;

6.2 If the Contractor is not the original manufacturer of the goods to be provided under the Contract, the Contractor shall provide PAHO or its designee with the benefit of all manufacturers warranties in addition to any other warranties required to be provided under the Contract;

6.3 The goods and/or services are of the quality, quantity and description required by the Contract, including when subjected to conditions prevailing in the place of final destination;

6.4 The goods and/or services are free from any right of claim by any third-party, including claims of infringement of any intellectual property rights, including, but not limited to, patents, copyright and trade secrets;

6.5 All goods are new and unused;

6.6 All warranties will remain fully valid following any delivery of goods and/or services for a period of not less than one (1) year following acceptance of the goods and/or services by PAHO or its designee in accordance with the Contract;

6.7 During any period in which the Contractors warranties are effective, upon notice by PAHO or its designee that the goods and/or services do not conform to the requirements of the Contract, the Contractor shall promptly and at its own expense:

6.7.1 correct the non-conformities,

6.7.2 replace defective goods with goods of the same or better quality, or

6.7.3 fully reimburse PAHO for the purchase price paid for the defective goods or services, and remove defective goods if applicable.

6.7.4 The Contractor shall remain responsive to the needs of PAHO or its designee for any services that may be required in connection with any of the Contractors warranties under the Contract

7. TITLE: The Contractor warrants and represents that the goods delivered under the Contract are unencumbered by any third partys title or other property rights, including, but not limited to, any liens or security interests. Unless otherwise expressly provided in the Contract, title in and to the goods shall pass from the Contractor to PAHO or its designee upon delivery of the goods and their acceptance by PAHO or its designee in accordance with the requirements of the Contract.

8. INTELLECTUAL PROPERTY: All rights, including title, copyright and patent rights in any material produced under the terms of this Contract shall be vested in PAHO or its designee, which shall be entitled to modify or change the materials as it deems fit. The Contractor acknowledges and agrees that such materials constitute works made for hire for PAHO and that the use or supply to PAHO of the goods or services rendered under this Contract does not infringe any patent, copyright, design, trade name or trademark.

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement
525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

9. **INDEMNIFICATION:** The Contractor shall indemnify, defend and hold PAHO harmless from any actions or claims brought against PAHO pertaining to the alleged infringement of a patent, copyright, design, trade name, or trademark arising in connection with the goods or services provided hereunder. The Contractor shall also indemnify, hold and save harmless and defend at its own expense PAHO, its officers, agents, servants and employees from and against all suits, claims, demands and liability of any nature or kind, including costs and expenses arising out of acts or omissions of the Contractor or the Contractors employees, servants or agents in the performance of this Contract.

10. **FAILURE TO PERFORM:** If the Contractor fails to deliver the goods or perform any of the services for any reason, including failure to obtain the necessary export licenses by the delivery date(s) specified in the Contract, PAHO may, after giving the Contractor reasonable notice to perform and without prejudice to any other rights or remedies under this Contract, exercise one or more of the following rights:

10.1. procure all or part of the goods and/or services from other sources and hold the Contractor responsible for any excess cost occasioned thereby;

10.2. refuse to accept delivery of all or parts of the goods and/or services;

10.3. terminate the Contract.

11. **PAYMENT:** PAHO shall, unless otherwise specified in this Contract, make payment within thirty (30) days of receipt of (a) the Vendors invoice or/and (b) copies of the customary shipping documents and other documents specified in the Contract, whichever of (a) or (b) is applicable and later.

12. **LIQUIDATED DAMAGES:** [X] Tick if NOT applicable

PAHO can claim liquidated damages from the Contractor and deduct 0.5% of the value of the Contract for each day of delay, up to a maximum of 10% of the value of the Contract, for late delivery of goods and/or services or for goods and/or services which do not meet the agreed specifications and are therefore rejected by PAHO or its designee. The payment or deduction of such liquidated damages shall not relieve the Contractor from any of its other obligations or liabilities under the Contract.

13. **INSURANCE:** [X] Tick if NOT applicable

The Contractor shall provide and thereafter maintain insurance against all risks with respect to its property and any equipment used for the execution of this Contract. The Contractor shall provide and thereafter maintain all appropriate workmens compensation insurance with respect to its employees to cover claims for personal injury or death in connection with this Contract. The Contractor shall also provide and thereafter maintain liability insurance in an adequate amount to cover third-party claims for death or bodily injury arising from or in connection with the provisions of service under this Contract and to cover the loss of or damage to property arising from or in connection with the provision of services under this Contract (including due to the operation of any vehicles, boats, airplanes or other equipment owned or leased by the Contractor or its agents, servants, employees or subcontractors). Such insurance policy(ies) shall be made out in the joint names of PAHO and the Contractor, and shall include rights of subrogation. The Contractor shall provide PAHO with a copy of all policy(ies) upon request.

14. **CONFIDENTIALITY:** "Confidential Information" is any information concerning or relating to the property, business or affairs of PAHO that is furnished to the Contractor or available to the Contractor because of this Contract. The Contractor shall treat all documents,

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037
Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

correspondence, decisions and orders concerning the Contract as confidential and restricted in nature and shall not divulge or allow access to them by any unauthorized person. The Contractor may not communicate at any time to any other person, Government or authority external to PAHO any information known to it by reason of its association with PAHO which has not been made public, without PAHOs written authorization. In addition, the Contractor shall not at any time use such information to private advantage. These obligations do not lapse upon termination of this Contract.

15. **PUBLICITY, ADVERTISING, AND USE OF THE PAHO NAME, EMBLEM, OR SEAL:** The Contractor shall not use the name, emblem or official seal of PAHO for any purpose other than as expressly authorized in writing by PAHO. The Contractor shall not advertise or otherwise make public that it is furnishing goods or services to PAHO without specific written permission from PAHO in each ıstance. The provisions of this paragraph shall survive completion of the Contract.

16. **MODIFICATION:** Neither party may change, modify or revise any aspect of this Contract unless the amendment is made in writing and signed by an authorized PAHO contracting officer and the Contractor.

17. **FORCE MAJEURE:** Notwithstanding Article 10, neither party shall be held responsible for delay, impossibility, or impracticability in fulfilling the terms of the Contract due to force majeure, which includes but is not limited to: war, riot, civil disorder, earthquake, fire, explosion, flood or other adverse weather conditions, strikes, confiscation or any other factors beyond its control, including but not limited to extraordinary measures taken by a government that adversely affect routine commercial transactions. The failure of the Contractor or PAHO to fulfill any of their obligations hereunder shall not be considered a breach of, or default under this Contract, insofar as such liability arises from an event of force majeure, provided that the affected party notifies the other and takes all reasonable precautions, due care and reasonable alternative measures, all with the objective of carrying out the terms and conditions of this Contract.

18. **TERMINATION:** This Contract may be terminated by PAHO upon written notice delivered to the Contractor at least fifteen (15) days prior to the effective date of termination. In the case of goods being manufactured or packaged to PAHO specifications, the contract may be terminated with at least 45 days written notice from the effective date of termination. In the event of termination, PAHO will compensate the Contractor for goods accepted by PAHO or services provided to PAHO and deemed by PAHO to be satisfactory.

9. **SETTLEMENT OF DISPUTES:** PAHO and the Contractor shall use their best efforts to settle amicably any dispute, controversy or claim arising out of, or relating to this Contract. Unless any such dispute, controversy or claim between the parties arising out of or relating to this Contract or the breach, termination or invalidity thereof is settled amicably within sixty (60) days after receipt by one Party of the other partys request for such amicable settlement, such dispute, controversy or claim shall be referred by either Party to arbitration in accordance with the UNCITRAL Arbitration Rules then in effect. The arbitral tribunal shall have no authority to award punitive damages. Any arbitration award rendered as a result of such arbitration shall be considered to be the final adjudication of any such controversy, claim or dispute and shall bind the parties.

20. **PRIVILEGES AND IMMUNITIES:** Nothing contained in this Contract shall be deemed a waiver, express or implied, of any immunity from suit, judicial process, confiscation, taxation, or any other immunity or privilege which PAHO may enjoy, whether pursuant to treaty, convention, law, order or decree of an international or national character or otherwise, or in accordance with international customary law.

21. **TAX EXEMPTION:** PAHO is exempt from payments of sales, use and excise taxes, and is exempt from customs duties and charges of a similar nature in respect of articles imported or exported for official use. PAHO may deduct from an invoice any such tax, duties or charges to which it may be entitled by reason of its privileges and immunities.

Pan American Health Organization (PAHO/WHO)
Regional Office of the World Health Organization
Office of Procurement

525 23rd Street N.W.
Washington, DC
20037

Telephone: 202-974-3000

PURCHASE ORDER

NO: APO20-00006260
Date: 03 Apr 2020

22. **ANTI-TERRORISM:** The Contractor certifies that it is not an individual or entity appearing on the New Consolidated List established and maintained by the United Nations Security Councils 1267 Committee. Contractor shall use best efforts to ensure that no funds provided under this Contract will be used to benefit, directly or indirectly, individuals or entities associated with terrorism.

23. **PAHO OFFICIAL NOT TO BENEFIT:** The Contractor warrants that no PAHO staff shall be permitted to any share or part of the Contract or any benefit that may otherwise arise therefrom. PAHO officials may not accept any type of gift or any offer of hospitality beyond that of nominal value. PAHO expects its Contractors not to offer any benefit such as free goods or services or a work position or sales opportunity to any current or former PAHO staff member in order to facilitate the suppliers business relationship with PAHO.

24. **SELF-DEALING:** The Contractor may not bid to supply goods or services to PAHO that may be directly or indirectly related to the goods or services provided under this Contract.

25. **SEVERABILITY:** Any provision of this Contract prohibited by the laws of any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition, without invalidating the remaining provisions of this Contract.

GOBIERNO DE EL SALVADOR | MINISTERIO DE SALUD

OPS/OMS EL SALVADOR

2019 NOV -4 PM 2:11

OFICIO Nº 2019-6008-515

San Salvador, 4 de noviembre de 2019.

DR. CARLOS ROBERTO GARZÓN
Representante de OPS/OMS en El Salvador
Presente.

Estimado Dr. Garzón:

En respuesta al oficio con Referencia N° SLV-COO-010/2-764 por medio del cual nos solicita la reconfirmación del requerimiento de vacuna para el primer y segundo trimestre del año 2020, al respecto adjuntamos el formulario PAHO que contiene el Plan de Inmunizaciones y Plan de Compra, así como el detalle de las necesidades por trimestre.

VACUNA	CANTIDAD SOLICITADA POR TRIMESTRE	
	PRIMER	SEGUNDO
BCG, 10 DOSIS	0	118,000
DPT, 10 DOSIS	175,000	0
Td (ADULTO), 10 DOSIS	360,000	360,000
DT PEDIATRICA, 10 DOSIS	0	2,200
HEPATITIS B PEDIATRICA, 1 DOSIS	0	98,600
SPR, 1 DOSIS	234,000	0
PENTAVALENTE, 1 DOSIS	200,500	200,500
ROTAVIRUS, 1 DOSIS	98,000	98,000
POLIO BIVALENTE, 20 DOSIS	180,000	180,000
ANTIRRABICA HUMANA (VEROCEL), 1 DOSIS	0	13,500
IPV, 10 DOSIS	158,300	158,300
NEUMOCOCO 13 VALENTE PEDIATRICA	156,000	156,000
VIRUS PAPILOMA HUMANO CUADRIVALENTE, 1 DOSIS	82,430	82,430
Tdpa (ADOLESCENTES/ADULTO)	0	94,000
FIEBRE AMARILLA, 10 DOSIS	23,000	0
INFLUENZA ESTACIONAL PEDIATRICA, 20 DOSIS	219,300	0
INFLUENZA, ESTACIONAL, ADULTO 10 DOSIS	1,100,000	0

No omito manifestarle que la solicitud enviada en memorándum N° 2019-6008-259 de fecha 21 de junio del presente año, queda sin efecto.

Sin otro particular, me suscribo de Usted muy atentamente.

DIOS UNION LIBERTAD

DRA. ANA ORELLANA BENDEK
Ministra de Salud

Con anexos

Hoja de Trabajo para Cálculo de Requerimientos Anual / Plan Regular y Complementario de Inmunización

Para: Organización Panamericana de la Salud (OPS)

525 23rd. St. N.W. Washington,D.C. 20037,USA Tel: +1 202-974-3884 Fax +1 202-974-3635

Fondo Rotatorio OPS para la Compra de Vacunas e Insumos

De:

País/Entidad: El Salvador MS

Fecha (dd/mm/aaaa): 03/11/2019

Tipo de Pronóstico: Plan Original / Base

Año Calendario: 2020

Organización Panamericana de la Salud

Organización Mundial de la Salud

Tabla 1: Plan Programático

					Plan de Rutina									Plan Complementario (Campañas)					Total
					Poblaciones a Vacunar **														
					0 a < 12 meses		12 a ≤ 23 meses		≥ 24 meses a 11 años		Otras Poblaciones (ej. Adolescentes, Adultos, Mujeres para HPV, etc)								
Código	Precalificadas por OMS (-)	Descripción	Dosis por vial	Factor de Pérdida	Población a vacunar	Dosis por persona	Población a vacunar	Dosis por persona	Población a vacunar	Dosis por persona	Población a vacunar	Dosis por persona	Demanda Total Anual (Dosis)	Factor de Pérdida	Población a vacunar	Dosis por persona	Comentarios acerca de Plan Complementario (ej. Campaña, población objetivo)	Demanda Total Anual (Dosis)	Total Demanda Plan Rutina + Complementario
359110-0101	SI	BCG (0.1 ml dosis) (10 dosis)	10	1.60	109,274	1							174,838					-	174,838
359120-0101	SI	DPT (10 dosis)	10	1.20					111,049	1			133,259					-	133,259
359130-0401	SI	DT (Adulto - Td) (10 dosis)	10	1.20							593,242	1	711,890					-	711,890
359130-0101	SI	DT (Pediátrica) (10 dosis)	10	1.20					3,534	1			4,241					-	4,241
359320-0101	SI	Hepatitis B Recomb. Pediátrica (1 dosis)	1		109,274	1							109,274					-	109,274
359320-0102	SI	Hepatitis B Recomb. Adulto (1 dosis)	1								7,542	3	22,626					-	22,626
359340-0107	SI	SRP (Cepa Leningrado-Zagreb de Parotiditis) (1 dosis)	1				109,690	1	110,230	1			219,920					-	219,920
359120-0118	SI	DPT Hep B Hib (Pentavalente) Líquida (1 dosis)	1		109,274	3	109,690	1					437,512					-	437,512
359550-0102	SI	Rotavirus líquida (Esquema Inmunización = 2 dosis) (1 dosis)	1		109,274	2							218,548					-	218,548
359180-0105	SI	Polio Oral BIVALENTE (bOPV) (10 / 20 dosis)	10 / 20	1.20	109,274	1	109,690	1	111,049	1			396,016					-	396,016
359440-0116	SI	Anti-Rábica Humana VEROCEL (1 dosis)	1								6,000	4	24,000					-	24,000
359210-0101	SI	Polio Inactivada (IPV) (5 / 10 dosis)	5 / 10	1.15	109,274	2							251,330					-	251,330
359480-0115	SI	Neumococo Conjug Pediátrica 13 valente (1 dosis)	1		56,136	2	9,000	1					121,272		169,690	1		169,690	290,962
359325-0002	SI	Virus Papiloma Humano cuadrivalente (1 dosis)	1						54,953	2			109,906					-	109,906
359120-0114	SI	Tdap (DTaP Adolescente/Adulto) (1 dosis)	1						109,274	1			109,274					-	109,274
359370-0103	SI	Fiebre Amarilla (10 dosis)	10	1.20							15,300	1	18,360					-	18,360
349430-0142	SI	Influenza Estac (HS)TRIVALENTE Ped (6 - 35 meses) (20 dosis)	20		54,637	2	109,960	1					219,234					-	219,234
359430-0146	SI	Influenza Estacional (HN) TRIVALENTE Adulto y Ped (> 3 años) (10 dosis)	10						221,742	1	880,740	1	1102,482					-	1102,482
-	-		0										-					-	-

Hoja de Trabajo para la Estimación Trimestral de Compra de Vacunas

Para: ORGANIZACIÓN PANAMERICANA DE LA SALUD

Oficina Regional para las Américas de la Organización Mundial de la Salud

525 23rd. St. N.W. Washington,D.C. 20037,USA Tel: +1 202-974-3884 Fax +1 202-974-3635

Pais o entidad: El Salvador ISSS

Fecha: 30/04/2020

Tipo de Pronóstico: Plan Original / Base

Año Calendario 2020

Control de Stock	
Símbolo	Rango (meses)
8	> 8
	4 8
	2 4
0	< 2

Fondo Rotatorio OPS para la Compra de Vacunas e Insumos

Tabla 2: Plan de Compra

			A) Cantidad Requerida Para Demanda y Stock Mínimo							B) Cantidad en Stock Proyectada a Inicio de Año							C) Programación de Compra Sugerida						
			Demanda Anual			Stock Mínimo Requerido			Total Requerido	Stock actual			Por recibir (dosis)	Por distribuir (dosis)	Stock Proyectado a Inicio de año a planificar		Compra Total Sugerida	Programación de Compra Trimestral					Revisión: Compra Programada vs. Sugerida
OMS Precalif.	Descripción	Dosis por Vial	Plan Regular	Plan Complemem (Campaña)	Cantidad Total	Demanda Mensual	Stock Mínimo Requerido		Total Demanda + Stock Mínimo	Fecha de Conteo de Stock	Conteo de Stock	Cobertura de Stock	de acuerdo a plan de compra	de acuerdo a plan de surtido a regiones				1er trim (Ene-Mar)	2do trim (Abr-Jun)	3er trim (Jul-Sep)	4to trim (Oct-Dic)	Compra Anual Programada	(+/- 5%)
			Dosis	Dosis	Dosis	Dosis	Meses	Dosis	Dosis	(dd/mm/aaaa)	Dosis	Meses	Dosis	Dosis	Dosis	Meses	Dosis	Dosis					
			A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U
					C = A+B	D = A/12		F = D x E	G = C + F			J = I / D			M = (I + K - L)	N = M / D	O = G - M					T = P+Q+R+S	Compara Columnas O y T
SI	BCG (0.05 ml dosis) (20 dosis)	20	209,000	-	209,000	17,417	3.0	52,250	261,250	24/04/2020	44,760		170,000	139,333	75,427		185,823	93,000	93,000			186,000	OK
SI	DPT (10 dosis)	10	133,259	-	133,259	11,105	3.0	33,315	166,574	24/04/2020	161,425	14.5		88,839	72,686		93,988	94,000				94,000	OK
SI	DT (Adulto - Td) (10 dosis)	10	550,000	-	550,000	45,833	3.0	137,500	687,500	24/04/2020	158,850		360,960	366,667	153,143		534,357	535,000				535,000	OK
SI	DT (Pediátrica) (10 dosis)	10	3,300	-	3,300	275	3.0	825	4,125	24/04/2020	-	-	2,200	2,200	-	-	4,125	4,125				4,125	OK
SI	Hepatitis B Recomb. Pediátrica (1 dosis)	1	110,000	-	110,000	9,167	3.0	27,500	137,500	24/04/2020	53,323		98,600	73,333	78,590	8.6	58,910	59,000				59,000	OK
SI	Hepatitis B Recomb. Adulto (1 dosis)	1	45,000	-	45,000	3,750	3.0	11,250	56,250	24/04/2020	8,793			30,000	(21,207)	(5.7)	77,457	77,500				77,500	OK
SI	SRP (Cepa Leningrado-Zagreb de Parotiditis) (1 dosis)	1	220,000	-	220,000	18,333	6.0	110,000	330,000	24/04/2020	-	-	234,000	146,667	87,333		242,667	121,300	121,300			242,600	OK
SI	DPT Hep B Hib (Pentavalente) Líquida (1 dosis)	1	440,000	-	440,000	36,667	6.0	220,000	660,000	24/04/2020	214,917		401,000	293,333	322,584	8.8	337,416	169,000	169,000			338,000	OK
SI	Rotavirus líquida (Esquema Inmunización = 2 dosis) (1 dosis)	1	220,000	-	220,000	18,333	6.0	110,000	330,000	24/04/2020	102,151		196,000	146,667	151,484	8.3	178,516	89,300	89,300			178,600	OK
SI	Polio Oral BIVALENTE (bOPV) (10 / 20 dosis)	10 / 20	397,259	-	397,259	33,105	6.0	198,629	595,888	24/04/2020	193,770		360,000	264,839	288,931	8.7	306,957	153,500	153,500			307,000	OK

Tabla 2: Plan de Compra

			A) Cantidad Requerida Para Demanda y Stock Mínimo							B) Cantidad en Stock Proyectada a Inicio de Año							C) Programación de Compra Sugerida						
			Demanda Anual			Stock Mínimo Requerido			Total Requerido	Stock actual			Por recibir (dosis)	Por distribuir (dosis)	Stock Proyectado a Inicio de año a planificar		Compra Total Sugerida	Programación de Compra Trimestral					Revisión: Compra Programada vs. Sugerida
OMS Precalif.	Descripción	Dosis por Vial	Plan Regular	Plan Complemem (Campaña)	Cantidad Total	Demanda Mensual	Stock Mínimo Requerido		Total Demanda + Stock Mínimo	Fecha de Conteo de Stock	Conteo de Stock	Cobertura de Stock	de acuerdo a plan de compra	de acuerdo a plan de surtido a regiones				1er trim (Ene-Mar)	2do trim (Abr-Jun)	3er trim (Jul-Sep)	4to trim (Oct-Dic)	Compra Anual Programada	(+/- 5%)
			Dosis	Dosis	Dosis	Dosis	Meses	Dosis	Dosis	(dd/mm/aaaa)	Dosis	Meses	Dosis	Dosis	Dosis	Meses	Dosis	Dosis					
SI	Anti-Rábica Humana VEROCEL (1 dosis)	1	28,000	-	28,000	2,333	3.0	7,000	35,000	24/04/2020	17,525		13,500	18,667	12,358		22,642	22,500				22,500	OK
SI	Polio Inactivada (IPV) (5 / 10 dosis)	5 / 10	242,000	-	242,000	20,167	6.0	121,000	363,000	24/04/2020			316,600	161,333	155,267		207,733	104,000	104,000			208,000	OK
SI	Neumococo Conjug Pediátrica 13 valente (1 dosis)	1	330,000	-	330,000	27,500	6.0	165,000	495,000	24/04/2020	37,059	1.3	312,000	220,000	129,059		365,941	183,000	183,000			366,000	OK
SI	Virus Papiloma Humano cuadrivalente (1 dosis)	1	180,000	-	180,000	15,000	3.0	45,000	225,000	24/04/2020	29,700	2.0	164,860	120,000	74,560		150,440	75,250	75,250			150,500	OK
SI	Tdap (DTaP Adolescente/Adulto) (1 dosis)	1	100,000	-	100,000	8,333	3.0	25,000	125,000	24/04/2020	45,039		94,000	66,667	72,372	8.7	52,628	53,000				53,000	OK
SI	Fiebre Amarilla (10 dosis)	10	16,500	-	16,500	1,375	3.0	4,125	20,625	24/04/2020	4,830		23,000	11,000	16,830	12.2	3,795	3,800				3,800	OK
SI	Influenza Estac (HS)TRIVALENTE Ped (6 - 35 meses) (20 dosis)	20	330,000	-	330,000	27,500		-	330,000						-		330,000	330,000				330,000	OK
SI	Influenza Estacional (HS) TRIVALENTE Adulto Adulto y Ped (> 3 años) (10 dosis)	10	1000,000	-	1000,000	83,333		-	1000,000						-	-	1000,000	1000,000				1000,000	OK
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	

Tabla 2: Plan de Compra

			A) Cantidad Requerida Para Demanda y Stock Mínimo							B) Cantidad en Stock Proyectada a Inicio de Año							C) Programación de Compra Sugerida						
			Demanda Anual			Stock Mínimo Requerido			Total Requerido	Stock actual			Por recibir (dosis)	Por distribuir (dosis)	Stock Proyectado a Inicio de año a planificar		Compra Total Sugerida	Programación de Compra Trimestral					Revisión: Compra Programada vs. Sugerida
OMS Precalif.	Descripción	Dosis por Vial	Plan Regular	Plan Complemem (Campaña)	Cantidad Total	Demanda Mensual	Stock Mínimo Requerido		Total Demanda + Stock Mínimo	Fecha de Conteo de Stock	Conteo de Stock	Cobertura de Stock	de acuerdo a plan de compra	de acuerdo a plan de surtido a regiones				1er trim (Ene-Mar)	2do trim (Abr-Jun)	3er trim (Jul-Sep)	4to trim (Oct-Dic)	Compra Anual Programada	
			Dosis	Dosis	Dosis	Dosis	Meses	Dosis	Dosis	(dd/mm/aaaa)	Dosis	Meses	Dosis	Dosis	Dosis	Meses	Dosis	Dosis					(+/- 5%)
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	
-	-	0	-	-	-	-		-	-						-		-					-	

* Vacunas no precalificadas por la OMS pero registradas por lo menos una de las siguientes Agencias Reguladoras: FDA/EUA, EMEA/Europa, BGTD/Canadá, TGA/Australia, KFDA/Corea, ANVISA/Brasil, COFEPRIS/Mexico, CECMED/Cuba y ANMAT (Argentina)

Comentarios

Agregar comentarios aquí

Nombre DRA. ANA ORELLANA BENDEK Firma ______ Fecha: 4-11-19

Representante Autorizado del Ministerio de Salud

Nombre DR. EDUARDO SUAREZ C. Firma ______ Fecha: 4.11.2019

Gerente del Programa Ampliado de Inmunizaciones

Nombre ______ Firma ______ Fecha: ______

Punto focal IM en la Representación OPS